Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06707610 · ClinicalTrials.gov registry record · Phase 1
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), and Antitumor Activity of ALK202 in Participants with Advanced Solid Tumors
A Phase 1 study of Advanced Solid Tumor and Advanced Cancer, sponsored by Shanghai Allink Biotherapeutics Co..
- Recruiting
- Registry status
- Phase 1
- Development phase
- 234
- Enrollment target
- 4
- Study locations
NCT06707610: Recruiting Phase 1 study of Advanced Solid Tumor and Advanced Cancer, sponsored by Shanghai Allink Biotherapeutics Co..
NCT06707610 is a Phase 1 study of Advanced Solid Tumor and Advanced Cancer that is actively recruiting participants, run by Shanghai Allink Biotherapeutics Co.. The registered enrollment target is 234 participants, above the 192-participant average among 189 other Advanced Solid Tumor trials with a reported enrollment target (22% higher). The trial reports 4 study locations across 3 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06707610, a Phase 1 study of Advanced Solid Tumor and Advanced Cancer, is actively recruiting participants, sponsored by Shanghai Allink Biotherapeutics Co..
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 234 participants
- Enrollment target
- 4
- Study locations
Study Summary
TThis is a first-in-human (FIH), open-label, multicenter dose escalation and expansion study of ALK202. The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (PK), and antitumor activity of ALK202 as a monotherapy in adult participants with Advanced Solid Tumors. The study will also identify recommended dose(s) for subsequent clinical studies of ALK202.
Primary Outcome
Dose-limiting toxicity (DLT); The incidence and severity of treatment-emergent adverse events (TEAEs) and treatment-related adverse events (TRAEs) according to CTCAE v5.0.
Conditions Studied
Interventions
- DRUG ALK202
Study Locations (4)
New South Wales
- Scientia Clinical Research Ltd - Randwick
- Macquarie University - Sydney
Florida
- D&H Cancer Research Center Llc - Margate
Virginia
- Next Oncology - Fairfax
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 234 participants |
| Start Date | 2025-02-10 |
| Est. Completion | 2028-12 |
| Phase | Phase 1 |
What NCT06707610 shows while recruiting
NCT06707610 is an interventional study that assigns participants to a tested intervention. The registered 234 participants enrollment target is mid-sized for trials with a published cap, above the 192-participant average among 189 other Advanced Solid Tumor trials with a reported enrollment target (22% higher).
The record links to 2 conditions, with Advanced Solid Tumor appearing as the primary indexed condition, and to 1 intervention - of which ALK202 is the first listed.
NCT06707610 reports a single indexed study location in New South Wales, Florida, Virginia.
Frequently Asked Questions
What is clinical trial NCT06707610 about?
NCT06707610 is a clinical study titled "A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), and Antitumor Activity of ALK202 in Participants with Advanced Solid Tumors". TThis is a first-in-human (FIH), open-label, multicenter dose escalation and expansion study of ALK202. The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (PK), and antitumor activity of ALK202 as a monotherapy in adult participants with Advanced Solid Tumors. The st...
What is the current status of trial NCT06707610?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 234 participants. The study started on 2025-02-10. Estimated completion is 2028-12.
What conditions does trial NCT06707610 study?
This clinical trial studies the following conditions: Advanced Solid Tumor, Advanced Cancer.
What interventions are being tested in trial NCT06707610?
The interventions under investigation include: ALK202 (DRUG).
Who is sponsoring clinical trial NCT06707610?
This trial is sponsored by Shanghai Allink Biotherapeutics Co., which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06707610 being conducted?
This trial has 4 study locations across Florida, Virginia, New South Wales. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Advanced Solid Tumor
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06707610's enrollment target sits among peer trials
234 52nd of 189 higher than 137 of 189 other Advanced Solid Tumor trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Advanced Solid Tumor trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
PM14 Administered Intravenously to Patients with Advanced Solid Tumors
RECRUITING · Phase 1
-
A Study of EP0031 in Patients With Advanced RET-altered Malignancies
RECRUITING · Phase 1
-
Study of AVZO-021 in Patients With Advanced Solid Tumors
RECRUITING · Phase 1
-
A First-in-Human Study of YL217 in Patients With Advanced Solid Tumors
RECRUITING · Phase 1
-
Study of Orally Administered MOMA-313 in Participants With Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
-
Phase I Study of Tolododekin Alfa (ANK-101) in Advanced Solid Tumors
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04942717 · 234 participants · NA
Adapting for Latinx Populations an Intervention That Involves Discussing and Sharing Patients' Health-Related Values
- NCT05208671 · 234 participants · NA
Nutrition to Optimize, Understand, and Restore Insulin Sensitivity in HIV for Oklahoma
- NCT05444465 · 234 participants · NA
Use of the REGENETEN™ Bioinductive Implant System in High Grade Partial-thickness Tears
- NCT05720338 · 234 participants · Phase 3
Is Intraperitoneal Drainage Necessary Following Distal Pancreatectomy?
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI